接受已解决或活跃的SARS-CoV-2感染的已故捐赠者的器官:欧洲委员会的一项调查。

IF 2.7 3区 医学 Q1 SURGERY
Transplant International Pub Date : 2024-11-21 eCollection Date: 2024-01-01 DOI:10.3389/ti.2024.13705
Maddalena Peghin, Elena Graziano, Maria De Martino, Maria Luisa Balsamo, Miriam Isola, Marta López-Fraga, Massimo Cardillo, Giuseppe Feltrin, Beatriz Domínguez-Gil González, Paolo Antonio Grossi
{"title":"接受已解决或活跃的SARS-CoV-2感染的已故捐赠者的器官:欧洲委员会的一项调查。","authors":"Maddalena Peghin, Elena Graziano, Maria De Martino, Maria Luisa Balsamo, Miriam Isola, Marta López-Fraga, Massimo Cardillo, Giuseppe Feltrin, Beatriz Domínguez-Gil González, Paolo Antonio Grossi","doi":"10.3389/ti.2024.13705","DOIUrl":null,"url":null,"abstract":"<p><p>SARS-CoV-2 infection represents a new challenge for solid organ transplantation (SOT) with evolving recommendations. A cross-sectional survey was performed (February-June 2024) to describe practices among Member States of the Council of Europe (COE) on the use of organs from deceased donors with resolved or active SARS-CoV-2 infection. Overall, 32 out of 47 Member States with a transplant program participated in the study. Four (12.5%) countries did not use organs from deceased donors either with resolved or with active SARS-CoV-2 infection and 8 (25%) countries accepted organs only from deceased donors with resolved SARS-CoV-2 infection. Donor evaluation for SARS-CoV-2 included universal screening with standard PCR testing on respiratory specimens generally (61.4%) performed within 24 h prior to organ recovery. Further microbiological, immunological and radiological investigations varied. Most waitlisted patients receiving organs from a deceased donor with active (94.5%) or resolved (61.5%) SARS-CoV-2 infection were preferred to have natural, vaccine-induced or hybrid SARS-CoV-2 immunity. Most countries did not require recipients to undergo specific anti-SARS-CoV-2 treatment as pre-exposure (0%), post-exposure prophylaxis (15.4%) or modification of immunosuppression regimen (24%). This study highlights similarities and heterogeneities in the management of SARS-CoV-2 positive donors between COE countries, and a potential to safely expand donors' pool.</p>","PeriodicalId":23343,"journal":{"name":"Transplant International","volume":"37 ","pages":"13705"},"PeriodicalIF":2.7000,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11617184/pdf/","citationCount":"0","resultStr":"{\"title\":\"Acceptance of Organs from Deceased Donors With Resolved or Active SARS-CoV-2 Infection: A Survey From the Council of Europe.\",\"authors\":\"Maddalena Peghin, Elena Graziano, Maria De Martino, Maria Luisa Balsamo, Miriam Isola, Marta López-Fraga, Massimo Cardillo, Giuseppe Feltrin, Beatriz Domínguez-Gil González, Paolo Antonio Grossi\",\"doi\":\"10.3389/ti.2024.13705\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>SARS-CoV-2 infection represents a new challenge for solid organ transplantation (SOT) with evolving recommendations. A cross-sectional survey was performed (February-June 2024) to describe practices among Member States of the Council of Europe (COE) on the use of organs from deceased donors with resolved or active SARS-CoV-2 infection. Overall, 32 out of 47 Member States with a transplant program participated in the study. Four (12.5%) countries did not use organs from deceased donors either with resolved or with active SARS-CoV-2 infection and 8 (25%) countries accepted organs only from deceased donors with resolved SARS-CoV-2 infection. Donor evaluation for SARS-CoV-2 included universal screening with standard PCR testing on respiratory specimens generally (61.4%) performed within 24 h prior to organ recovery. Further microbiological, immunological and radiological investigations varied. Most waitlisted patients receiving organs from a deceased donor with active (94.5%) or resolved (61.5%) SARS-CoV-2 infection were preferred to have natural, vaccine-induced or hybrid SARS-CoV-2 immunity. Most countries did not require recipients to undergo specific anti-SARS-CoV-2 treatment as pre-exposure (0%), post-exposure prophylaxis (15.4%) or modification of immunosuppression regimen (24%). This study highlights similarities and heterogeneities in the management of SARS-CoV-2 positive donors between COE countries, and a potential to safely expand donors' pool.</p>\",\"PeriodicalId\":23343,\"journal\":{\"name\":\"Transplant International\",\"volume\":\"37 \",\"pages\":\"13705\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2024-11-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11617184/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Transplant International\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3389/ti.2024.13705\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplant International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/ti.2024.13705","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0

摘要

SARS-CoV-2感染是实体器官移植(SOT)面临的新挑战,建议也在不断发展。进行了一项横断面调查(2024年2月至6月),以描述欧洲委员会(COE)成员国在使用已确诊或活动性SARS-CoV-2感染的已故捐赠者器官方面的做法。总的来说,47个有移植项目的成员国中有32个参与了这项研究。4个(12.5%)国家未使用已确诊或已确诊的SARS-CoV-2感染的死亡供体的器官,8个(25%)国家仅接受已确诊的SARS-CoV-2感染的死亡供体的器官。供体对SARS-CoV-2的评估包括在器官恢复前24小时内对呼吸标本进行标准PCR检测的普遍筛查(61.4%)。进一步的微生物学、免疫学和放射学调查各不相同。大多数等待接受SARS-CoV-2感染活动性(94.5%)或消退性(61.5%)的已故供者器官的患者更倾向于具有自然、疫苗诱导或混合型SARS-CoV-2免疫力。大多数国家不要求接受者接受特异性抗sars - cov -2治疗,如暴露前(0%)、暴露后预防(15.4%)或修改免疫抑制方案(24%)。这项研究强调了COE国家之间在管理SARS-CoV-2阳性供体方面的相似性和异质性,以及安全扩大供体库的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Acceptance of Organs from Deceased Donors With Resolved or Active SARS-CoV-2 Infection: A Survey From the Council of Europe.

SARS-CoV-2 infection represents a new challenge for solid organ transplantation (SOT) with evolving recommendations. A cross-sectional survey was performed (February-June 2024) to describe practices among Member States of the Council of Europe (COE) on the use of organs from deceased donors with resolved or active SARS-CoV-2 infection. Overall, 32 out of 47 Member States with a transplant program participated in the study. Four (12.5%) countries did not use organs from deceased donors either with resolved or with active SARS-CoV-2 infection and 8 (25%) countries accepted organs only from deceased donors with resolved SARS-CoV-2 infection. Donor evaluation for SARS-CoV-2 included universal screening with standard PCR testing on respiratory specimens generally (61.4%) performed within 24 h prior to organ recovery. Further microbiological, immunological and radiological investigations varied. Most waitlisted patients receiving organs from a deceased donor with active (94.5%) or resolved (61.5%) SARS-CoV-2 infection were preferred to have natural, vaccine-induced or hybrid SARS-CoV-2 immunity. Most countries did not require recipients to undergo specific anti-SARS-CoV-2 treatment as pre-exposure (0%), post-exposure prophylaxis (15.4%) or modification of immunosuppression regimen (24%). This study highlights similarities and heterogeneities in the management of SARS-CoV-2 positive donors between COE countries, and a potential to safely expand donors' pool.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Transplant International
Transplant International 医学-外科
CiteScore
4.70
自引率
6.50%
发文量
211
审稿时长
3-8 weeks
期刊介绍: The aim of the journal is to serve as a forum for the exchange of scientific information in the form of original and high quality papers in the field of transplantation. Clinical and experimental studies, as well as editorials, letters to the editors, and, occasionally, reviews on the biology, physiology, and immunology of transplantation of tissues and organs, are published. Publishing time for the latter is approximately six months, provided major revisions are not needed. The journal is published in yearly volumes, each volume containing twelve issues. Papers submitted to the journal are subject to peer review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信